Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Alessio Mazzoni, … , Francesco Annunziato, Lorenzo Cosmi
Alessio Mazzoni, … , Francesco Annunziato, Lorenzo Cosmi
Published May 28, 2020
Citation Information: J Clin Invest. 2020;130(9):4694-4703. https://doi.org/10.1172/JCI138554.
View: Text | PDF
Clinical Medicine Immunology Infectious disease

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Abstract

BACKGROUND Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options.METHODS We performed a flow cytometric characterization of immune cell subsets from 30 patients with COVID-19 and correlated these data with clinical outcomes.RESULTS Patients with COVID-19 showed decreased numbers of circulating T, B, and NK cells and exhibited a skewing of CD8+ T cells toward a terminally differentiated/senescent phenotype. In agreement, CD4+ T and CD8+ T, but also NK cells, displayed reduced antiviral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in patients with COVID-19, particularly in those who required intensive care. The latter group of patients also showed increased serum IL-6 levels that inversely correlated to the frequency of granzyme A–expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells.CONCLUSION The association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore antiviral mechanisms.FUNDING This study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (the ex-60% fund and the “Excellence Departments 2018–2022 Project”) derived from Ministero dell’Istruzione, dell’Università e della Ricerca (Italy).

Authors

Alessio Mazzoni, Lorenzo Salvati, Laura Maggi, Manuela Capone, Anna Vanni, Michele Spinicci, Jessica Mencarini, Roberto Caporale, Benedetta Peruzzi, Alberto Antonelli, Michele Trotta, Lorenzo Zammarchi, Luca Ciani, Leonardo Gori, Chiara Lazzeri, Andrea Matucci, Alessandra Vultaggio, Oliviero Rossi, Fabio Almerigogna, Paola Parronchi, Paolo Fontanari, Federico Lavorini, Adriano Peris, Gian Maria Rossolini, Alessandro Bartoloni, Sergio Romagnani, Francesco Liotta, Francesco Annunziato, Lorenzo Cosmi

×

Figure 2

Frequency of CD4+ and CD8+ T cell subsets in patients with COVID-19.

Options: View larger image (or click on image) Download as PowerPoint
Frequency of CD4+ and CD8+ T cell subsets in patients with COVID-19. (A)...
(A) Frequency of naive (CD45RA+CCR7+), central memory (CD45RA–CCR7+), effector memory (CD45RA–CCR7–), TEMRA (CD45RA+CCR7–), and HLA-DR+ cells among CD4+ T cells in healthy controls (black dots) and COVID-19 patients (gray dots). (B) Frequency of naive (CD45RA+CCR7+), central memory (CD45RA–CCR7+), effector memory (CD45RA–CCR7–), TEMRA (CD45RA+CCR7–), senescent (CD57+), and HLA-DR+ cells among CD8+ T cells in healthy controls (black dots) and COVID-19 patients (gray dots). Red lines represent mean values for each population. Data obtained from 8 healthy controls and 21 COVID-19 patients. *P < 0.05; **P < 0.01; ***P < 0.001; calculated with Student’s t test.